title: Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
abstract: To understand the rate-limiting process of oral drug absorption, not only total bioavailability (F) but also intestinal (F(a) · F(g)) and hepatic (F(h)) availability after oral administration should be evaluated. Usually, F(a) · F(g) of drug is calculated from pharmacokinetic parameters after intravenous and oral administration. This approach is influenced markedly by the estimated value of F(h), which varies with the hepatic blood flow used in the calculations. In this study, portal vein-cannulated rats were used to calculate the F(a) · F(g) of drugs from a single oral dosing experiment without data from intravenous injection. Portal vein-cannulated rats were prepared by a new operative method that enables stable portal vein blood flow. This surgery had no effects on hepatic blood flow and metabolic activity. Our method for calculating F(a) · F(g) was validated by determining both portal and systemic plasma concentration profiles of various drugs possessing different pharmacokinetic properties after oral administration to the portal vein-cannulated rats. Simulation of portal and systemic plasma concentrations by physiologically based pharmacokinetic modeling indicated that the balance of the absorption rate constant (k(a)) and elimination rate constant (k(e)) resulted in different patterns in portal and systemic plasma concentration-time profiles. This study is expected to provide a new experimental animal model that enables identification of the factors that limit oral bioavailability and to provide pharmacokinetic information on the oral absorption process of drugs during drug discovery.
authors.affiliation: Pharmacokinetics and Safety Research Department, Central Research Laboratories, Kaken Pharmaceutical Co., Ltd. 14, Shinomiya Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan. matsuda_yoshiki@kaken.co.jp
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Konno
authors.forename: Masahiro
authors.initials: M
authors.lastname: Satsukawa
authors.forename: Taro
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yu
authors.initials: Y
authors.lastname: Takimoto
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Morisaki
authors.forename: Shinji
authors.initials: S
authors.lastname: Yamashita
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000983:Antipyrine / Q000378:metabolism; D001682:Biological Availability; D002404:Catheterization; D007408:Intestinal Absorption / Q000502:physiology*; D007413:Intestinal Mucosa / Q000378:metabolism*; D008099:Liver / Q000098:blood supply / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D010599:Pharmacokinetics; D011169:Portal Vein / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000502:physiology
chemical_list: D000983:Antipyrine